Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Total Valuation
Nautilus Biotechnolgy has a market cap or net worth of $85.45M. The enterprise value is -$858.81K.
Market Cap$85.45M
Enterprise Value-$858.81K
Share Statistics
Nautilus Biotechnolgy has 126,148,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,148,470
Owned by Insiders42.96%
Owned by Institutions0.02%
Financial Efficiency
Nautilus Biotechnolgy’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-528.21K
Employee Count134
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nautilus Biotechnolgy is -2.98. Nautilus Biotechnolgy’s PEG ratio is -0.30.
PE Ratio-2.98
PS Ratio0.00
PB Ratio1.01
Price to Fair Value1.01
Price to FCF-3.44
Price to Operating Cash Flow-3.56
PEG Ratio-0.30
Income Statement
In the last 12 months, Nautilus Biotechnolgy had revenue of 0.00 and earned -70.78M in profits. Earnings per share was -0.56.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-70.78M
Net Income-70.78M
EBITDA-64.43M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was -56.82M and capital expenditures -1.69M, giving a free cash flow of -58.51M billion.
Operating Cash Flow-56.82M
Free Cash Flow-58.51M
Free Cash Flow per Share-0.46
Dividends & Yields
Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.98
52-Week Price Change-75.89%
50-Day Moving Average0.96
200-Day Moving Average1.99
Relative Strength Index (RSI)37.97
Average Volume (3m)185.75K
Important Dates
Nautilus Biotechnolgy upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date―
Financial Position
Nautilus Biotechnolgy as a current ratio of 17.40, with Debt / Equity ratio of 15.09%
Current Ratio17.40
Quick Ratio17.40
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nautilus Biotechnolgy has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nautilus Biotechnolgy EV to EBITDA ratio is -3.31, with an EV/FCF ratio of -3.49.
EV to Sales0.00
EV to EBITDA-3.31
EV to Free Cash Flow-3.49
EV to Operating Cash Flow-3.61
Balance Sheet
Nautilus Biotechnolgy has $138.81M in cash and marketable securities with $29.34M in debt, giving a net cash position of -$109.47M billion.
Cash & Marketable Securities$138.81M
Total Debt$29.34M
Net Cash-$109.47M
Net Cash Per Share-$0.87
Tangible Book Value Per Share$1.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nautilus Biotechnolgy is $2.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.75
Price Target Upside304.41% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-1.20%